Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors
Shanghai Zhongshan Hospital
Shanghai Zhongshan Hospital
Changhai Hospital
Xijing Hospital
National Taiwan University Hospital
Second Affiliated Hospital, School of Medicine, Zhejiang University
Medstar Health Research Institute
Guangxi Medical University
Guangxi Medical University
Seoul National University Hospital
Medical Research Council
National Cancer Institute (NCI)
National Cancer Institute (NCI)